— Dr. Tannenbaum’s successful track record in driving business excellence to help drive the company’s execution of Purified Cortrophin GelMT launch —
BAUDETTE, Minnesota, March 22, 2022–(BUSINESS WIRE)–ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced the addition of Renee P. Tannenbaum, Pharm.D., MBA, to its Board of administration. Dr. Tannenbaum has over 35 years of management experience in the pharmaceutical industry. This appointment is effective immediately and brings ANI’s Board of Directors to nine members.
“We are honored to bring Dr. Tannenbaum’s extensive biopharmaceutical business experience and expertise to our Board of Directors. With his many accomplishments and proven track record of developing and implementing innovative business strategies and growth, Dr. Tannenbaum will be a great asset to the Company, especially as we move forward with the commercialization of Purified Cortrophin Gel. said Patrick D. Walsh, Chairman of ANI’s Board of Directors.
“I am delighted to join the Board of Directors at this pivotal moment in ANI’s trajectory. With the acquisition of Novitium complete and the launch of Cortrophin Gel underway, the company has many exciting years ahead of it, and I I look forward to sharing my insights with management along the way,” Dr. Tannenbaum said.
Dr. Tannenbaum is a strategic advisor to several biopharmaceutical and device companies and serves on the board of directors of Cardiff Oncology, Inc. and as an advisor to the board of directors of Aerami Therapeutics, Inc. She was previously vice president of global partnership at Halozyme, Inc. and Head of Global Customer Excellence at AbbVie, where she was responsible for building the organization’s business capabilities.
Previously, Dr. Tannenbaum served as President of Myrtle Potter & Company, LLC, a global life science consulting and advisory firm and Executive Vice President and Chief Commercial Officer at Elan Pharmaceuticals, Inc., where she was responsible, among others, revenue generation for products marketed by Elan, preparing for commercialization of the Company’s pipeline and strengthening the Company’s overall commercial capabilities. Prior to her role at Elan, Dr. Tannenbaum was at Novartis Pharma AG, where she led the global business operations organization. She also spent nine years at Bristol Myers Squibb and 16 years at Merck and Company, Inc., where she held various management positions.
Dr. Tannenbaum previously served on the boards of Zogenix, Inc., Nordic Nanovector ASA, Cipher Pharmaceuticals, Inc., Sharps Compliance Inc., and Immune Pharmaceuticals, Inc., and maintains a professorship at Mayes College at the University of Science. business and health policy. Dr. Tannenbaum received his Doctor of Pharmacy from the Philadelphia College of Pharmacy and Sciences, his MBA from Temple University, and his Bachelor of Science in Pharmacy from the University of Connecticut.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals is a diversified biopharmaceutical company serving patients in need by developing, manufacturing and marketing high-quality branded and generic pharmaceutical products, including for diseases of high unmet medical need. Our team is focused on delivering sustainable growth by building a successful franchise of Purified Cortrophin™ Gel, strengthening our generics business with enhanced development capability, innovating in established brands and leveraging our North American manufacturing. For more information, please visit www.anipharmaceuticals.com.
To the extent that statements made in this release relate to information that is not historical, they are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as that “anticipates”, “will”, “expects”, “plans”, “potential”, “future”, “believes”, “intends”, “continues”, other words of similar meaning, derivations of these words and use of future dates.These forward-looking statements include statements regarding the commercialization of Cortrophin Gel, and the expansion of ANI’s business following the recent acquisition of Novitium Pharma LLC. and uncertainties that could cause the Company’s actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, costs related to the commercialization of Cortrophin Gel, the ability to maintain regulatory approval of the product and maintaining sufficiency of the product, ability to obtain reimbursement from third-party payers for this product, changes in government legislation, opinions and views of key opinion leaders and physicians who treat patients with chronic conditions and who may prescribe Cortrophin Gel, manufacturing difficulties or delays, ANI’s ability to generate projected net product revenues and gain market share on a timely basis, actions taken by competitors in response to a new market entrant, ANI’s reliance on third parties over which it does not always have full control, costs and regulatory requirements relating to contract manufacturing agreements , increased competition and the strategies employed by competitors, uncertainties regarding the COVID-19 pandemic, market trends for our products, the environmental regulatory developments and changes, including healthcare reform legislation, risks associated with the integration of Novitium and whether ANI will obtain the anticipated benefits from the acquisition that it currently expects and other risks and uncertainties described in ANI’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports filed with the United States Securities and Exchanges Commission.
All forward-looking statements contained in this press release speak only as of the date of this press release and are based on the Company’s current beliefs, assumptions and expectations. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220322006042/en/
Lisa M. Wilson
Onsite Communications, Inc.